SCHEMBL25746247

SCHEMBL25746247

CC(F)(F)c1cc(N)n[nH]1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MITF O75030 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ DYRK1A Q13627 1/20 0.34
▸ MKNK1 Q9BUB5 1/20 0.33
▸ MKNK2 Q9HBH9 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ IKBKB O14920 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ GFER P55789 1/20 0.33
▸ PDPK1 O15530 1/20 0.32
▸ GAA P10253 1/20 0.31
▸ HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923978 0.82 ALDH1A1 (0.48) ALDH1A1KMT2AMITFTP53SMN1; SMN2
SCHEMBL1770329 0.82 SMN1; SMN2 (0.46) ALDH1A1KMT2AMITFTP53SMN1; SMN2
SCHEMBL24007686 0.78 MCL1 (0.45) ALDH1A1KMT2AMITFTP53SMN1; SMN2
SCHEMBL22109258 0.78 ALDH1A1 (0.46) ALDH1A1KMT2AMITFTP53SMN1; SMN2
SCHEMBL24816445 0.74 ALDH1A1 (0.39) ALDH1A1KMT2AMITFTP53SMN1; SMN2
SCHEMBL2478382 0.71 MITF (0.37) ALDH1A1KMT2AMITFTP53SMN1; SMN2
SCHEMBL18695537 0.69 — —
SCHEMBL18695578 0.69 HPGD (0.31) TP53HSD17B10HPGD
SCHEMBL28860793 0.68 HCAR2 (0.53) —
SCHEMBL22125931 0.66 MITF (0.33) ALDH1A1KMT2AMITFTP53DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2023-08-24 — — US disclosed
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265075-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B ALDH1A1 3735/4885KMT2A 462/4885MITF 1560/4885
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B ALDH1A1 3735/4885KMT2A 462/4885MITF 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback